Skip to main content
. 2016 May 18;7(24):37000–37012. doi: 10.18632/oncotarget.9454

Figure 7. Epidermal growth factor receptor (EGFR) is essential for the effects of GLRX3 on inhibiting pAkt.

Figure 7

(A–C) Real-time RT-PCR assay of mRNA levels of EGFR in shGLRX3-HONE1/CNE2 and shCtrl-HONE1/CNE2 cells (A), and western blot (B) and immunofluorescence (C) assay of protein levels. Data are mean ± SD from three experiments. (D) pAkt detection in shGLRX3-HONE1 and shGLRX3-CNE2 cells treated with and without EGFR stimulator 100 ng/ml EGF for 48 h, followed by western blot analysis. (**p < 0.01)